China: Green Valley Alzheimer’s Trial; Samsung Biologics…
A roundup of the latest from Chinese pharma, including Green Valley's upcoming US trial for an Alzheimer's drug inspired by algae; Samsung Biologics…
Tagged with Alzheimer's
Aducanumab edges closer to Potential Approval: Next up, the…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
Opinion: The Paradigm Shift Needed for Effective Alzheimer’s…
Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech…
Luis Calderon – General Manager, Biogen Mexico
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and…
Worried About Biogen’s Aducanumab? Don’t Be
Dr Neil Cashman examines the recent news around Biogen's Alzheimer's treatment aducanumab, assuages some investor fears, and underlines the…
Alzheimer’s Disease Treatment: Canadian-Led Innovation…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen's aducanumab on the search for Alzheimer's Disease (AD) treatments, and…
Gunilla Osswald – CEO, BioArctic, Sweden
BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for…
Sweden’s BioArctic: A Potential Paradigm Shift in Alzheimer’s…
Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the…
Alzheimer’s Disease R&D Expenditure Snapshot 2019
Alzheimer's drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, "Except for…
The Ongoing Battle to Crack the Alzheimer’s Treatment Dilemma
David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness…
